Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.

IF 2 4区医学 Q2 OPHTHALMOLOGY Ocular Immunology and Inflammation Pub Date : 2016-10-01 Epub Date: 2015-09-23 DOI:10.3109/09273948.2015.1025984

J Fernando Arevalo, Andres F Lasave, Vishali Gupta, Igor Kozak, Mosa Barakat Al Harbi, Abdulaziz Adel Al Rushood, Hassan A Al Dhibi

{"title":"Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.","authors":"J Fernando Arevalo, Andres F Lasave, Vishali Gupta, Igor Kozak, Mosa Barakat Al Harbi, Abdulaziz Adel Al Rushood, Hassan A Al Dhibi","doi":"10.3109/09273948.2015.1025984","DOIUrl":null,"url":null,"abstract":"Purpose: To describe the clinical characteristics and treatment outcomes of Vogt-Koyanagi-Harada (VKH) disease over a 12-year period.Methods: A retrospective chart review was used to identify VKH patients, from January 1999 to December 2011.Results: In total, 154 patients (308 eyes) were diagnosed with VKH. The mean age at diagnosis was 33.8 ± 13 years. Mean baseline best-corrected visual acuity (BCVA) was 20/125; (0.8 ± 0.6 logMAR). Recurrent episodes occurred in 107 (54%) patients. Oral prednisone was administered in all patients. At the last visit, the mean BCVA was 20/50 (0.4 ± 0.7 logMAR). The most common complications post-treatment were: glaucoma [104 (33.8%) eyes] and cataract [84 (27.2%) eyes].Conclusions: In Saudi Arabia, VKH-related uveitis is predominant in young females. Bilateral panuveitis is the most common ocular manifestation and near 50% of eyes present with exudative retinal detachment. Oral prednisone was the primary treatment and the majority of eyes maintained 20/50 or better vision.","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":"24 5","pages":"521-9"},"PeriodicalIF":2.0000,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/09273948.2015.1025984","citationCount":"31","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Immunology and Inflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3109/09273948.2015.1025984","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/9/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 31

Abstract

Purpose: To describe the clinical characteristics and treatment outcomes of Vogt-Koyanagi-Harada (VKH) disease over a 12-year period.

Methods: A retrospective chart review was used to identify VKH patients, from January 1999 to December 2011.

Results: In total, 154 patients (308 eyes) were diagnosed with VKH. The mean age at diagnosis was 33.8 ± 13 years. Mean baseline best-corrected visual acuity (BCVA) was 20/125; (0.8 ± 0.6 logMAR). Recurrent episodes occurred in 107 (54%) patients. Oral prednisone was administered in all patients. At the last visit, the mean BCVA was 20/50 (0.4 ± 0.7 logMAR). The most common complications post-treatment were: glaucoma [104 (33.8%) eyes] and cataract [84 (27.2%) eyes].

Conclusions: In Saudi Arabia, VKH-related uveitis is predominant in young females. Bilateral panuveitis is the most common ocular manifestation and near 50% of eyes present with exudative retinal detachment. Oral prednisone was the primary treatment and the majority of eyes maintained 20/50 or better vision.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

三级中心Vogt-Koyanagi-Harada病患者12年的临床结果

目的:描述Vogt-Koyanagi-Harada (VKH)病12年的临床特点和治疗结果。方法:对1999年1月至2011年12月的VKH患者进行回顾性分析。结果:共154例(308眼)被诊断为VKH。平均诊断年龄33.8±13岁。平均基线最佳矫正视力(BCVA)为20/125;(0.8±0.6 logMAR)。107例(54%)患者复发。所有患者均口服强的松。最后一次就诊时，平均BCVA为20/50(0.4±0.7 logMAR)。术后最常见的并发症为青光眼104眼(33.8%)、白内障84眼(27.2%)。结论:在沙特阿拉伯，vkh相关的葡萄膜炎以年轻女性为主。双侧全葡萄膜炎是最常见的眼部表现，近50%的眼睛表现为渗出性视网膜脱离。口服强的松是主要治疗方法，大多数眼睛保持20/50或更好的视力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Ocular Immunology and Inflammation 医学-眼科学

CiteScore

6.20

自引率

15.20%

发文量

285

审稿时长

6-12 weeks

期刊介绍： Ocular Immunology & Inflammation ranks 18 out of 59 in the Ophthalmology Category.Ocular Immunology and Inflammation is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and vision scientists. Published bimonthly, the journal provides an international medium for basic and clinical research reports on the ocular inflammatory response and its control by the immune system. The journal publishes original research papers, case reports, reviews, letters to the editor, meeting abstracts, and invited editorials.